Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Viva Bio and Schrödinger to Collaborate on Structure-based Drug Discovery

publication date: Jul 28, 2020

Viva Biotech, a Shanghai discovery CRO, and Schrödinger of New York City will collaborate to expand structure-based drug discovery by generating de novo crystal structures of targets. Schrödinger will identify high-value drug discovery targets for which there aren't any crystal structures in the public domain. Viva will use its X-ray crystallography technology to generate high-resolution structures with bound ligands. Schrödinger will then apply its AI computational platform to design novel therapeutic candidates for the targets. More details....

Stock Symbols: (HK: 1873) (NSDQ: SDGR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.